J&J’s Ottava Robot Poised to Revolutionize Surgical Innovation

Johnson & Johnson has received FDA approval for an investigational device exemption (IDE) to begin U.S. clinical trials of its Ottava surgical robot. Positioned to rival Intuitive Surgical's da Vinci system, Ottava is designed to address unmet needs in robotic-assisted surgery. The system features a unique architecture with four arms integrated into the operating table, enabling seamless transitions between robotic, laparoscopic, hybrid, and open procedures. Additionally, Ottava’s compact design and Ethicon-compatible surgical instruments aim to enhance precision and consistency across surgical modalities.

​

Ottava's integrated Polyphonic digital system further distinguishes it by connecting robotics, software, and surgical technologies to provide real-time data and insights for clinical decision-making. By combining J&J's MedTech expertise with innovative design, Ottava seeks to expand competition in the high-growth robotic surgery market while improving surgical efficiency and outcomes. As J&J prepares trial sites and trains investigators, the Ottava platform represents a significant step forward in the evolution of surgical robotics.